Immix Biopharma, Inc.

IMMX

US45258H1068

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
7.330 ^USD	-1.35%		+8.75%	+40.15%

Feb. 09	Mizuho Initiates Immix Biopharma at Outperform With $14 Price Target	MT
Jan. 28	Immix Biopharma Says US FDA Granted Breakthrough Therapy Designation to NXC-201	MT

Immix Biopharma to offer and sell up to $750 million in securities - SEC filing

Published on 01/09/2026 at 06:19 pm EST

Reuters

Latest news about Immix Biopharma, Inc.

Feb. 09	Mizuho Initiates Immix Biopharma at Outperform With $14 Price Target	MT
Jan. 28	Immix Biopharma Says US FDA Granted Breakthrough Therapy Designation to NXC-201	MT
Jan. 28	Immix Biopharma, Inc. Receives U.S. FDA Breakthrough Therapy Designation for NXC-201	CI
Jan. 09	Immix Biopharma to offer and sell up to $750 million in securities - SEC filing	RE
Dec. 09	Immix Biopharma announces closing of upsized $100 million underwritten offering of common stock and pre-funded warrants	RE
Dec. 08	Immix Biopharma Prices $100 Million Offering	MT
Dec. 08	Immix Biopharma Prices $100 Million Offering	MT
Dec. 07	Immix Biopharma prices offering of 19.1 million shares at $5.10 per share	RE
Dec. 07	Immix Biopharma, Inc. Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-In-Class Therapy for Relapsed/Refractory AL Amyloidosis	CI
Nov. 12	Immix Biopharma, Inc. Appoints Michael Grabow as Chief Commercial Officer	CI
Nov. 07	Immix Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-09-18	Immix Biopharma says that 50% enrollment has already been surpassed in NEXICART-2	RE
25-09-18	Immix Biopharma, Inc. Announces 50% Enrollment Milestone Surpassed in Its Ongoing Relapsed/Refractory AL Amyloidosis Clinical Trial, NEXICART-2	CI
25-09-08	Immix Biopharma Gets Strategic Investment	MT
25-09-08	Immix Biopharma announces strategic investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang	RE

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).

Employees

Sector

Biotechnology & Medical Research

More about the company